EDIT · XBRL financial data

Editas Medicine financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EDIT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	5	year only	1	1	0	31*	5	4	8	25*	3	12
Research and development	41	70*	49	54	48	49*	27	16	20	27*	18	20
General and administrative	15	14*	19	18	18	16*	13	13	12	11*	10	12
Total operating expenses	55	84*	68	72	66	77*	81	55	32	32*	28	30
Operating income (loss)	(50)	(24)*	(67)	(72)	(66)	(47)*	(76)	(52)	(25)	(8)*	(25)	(19)
Interest expense	—	—	0	0	0	2*	2	0*	2	(0)*	5	0*
Other income (expense)	0	(0)*	0	(0)	(0)	(0)*	(0)	(2)	(0)	(0)*	(0)	0
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(45)	(19)*	(62)	(68)	(62)	(45)*	(76)	(53)	(25)	(6)*	(25)	(18)
Earnings per share, basic USD per share	(0.55)	(0.23)*	(0.76)	(0.82)	(0.75)	(0.55)*	(0.92)	(0.63)	(0.28)	(0.06)*	(0.26)	(0.15)
Earnings per share, diluted USD per share	(0.55)	(0.23)*	(0.76)	(0.82)	(0.75)	(0.55)*	(0.92)	(0.63)	(0.28)	(0.06)*	(0.26)	(0.15)
Weighted average shares, basic millions of shares	82	82*	82	82	82	83*	83	84	90	97*	98	119
Weighted average shares, diluted millions of shares	82	82*	82	82	82	83*	83	84	90	97*	98	119

Fiscal quarters (EDIT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	83	124	69	64	96	132	139	139	166	147	124	182
Marketable securities	267	199	227	215	169	138	82	40	0	0	—	30
Marketable securities, non-current	97	104	81	39	0	0	—	—	—	—	—	—
Prepaid and other current assets	7	8	9	7	6	3	3	4	3	2	2	4
Total current assets	359	341	306	286	271	289	225	183	177	164	128	218
Property and equipment, net	12	12	13	14	15	14	8	5	4	4	3	3
Right-of-use asset	32	34	31	37	36	33	26	19	18	16	15	14
Total assets	505	499	440	385	328	342	264	211	202	187	149	237
Accounts payable	10	8	8	14	12	5	5	7	3	3	4	5
Accrued liabilities	30	35	31	28	29	46	47	48	48	33	21	17
Current portion of long-term debt	—	0	—	—	—	5	5	5	5	5	8	8
Total current liabilities	59	63	66	74	72	77	73	66	62	46	40	68
Long-term debt	—	0	—	—	—	52	50	52	54	54	47	48
Lease liability, non-current	25	24	22	21	22	20	18	15	14	12	11	9
Total liabilities	144	150	146	153	152	207	201	191	188	159	145	132
Accumulated deficit	(1,212)	(1,231)	(1,293)	(1,361)	(1,423)	(1,468)	(1,545)	(1,598)	(1,623)	(1,629)	(1,653)	(1,672)
Total stockholders' equity	360	349	294	232	176	134	62	19	13	27	4	105
Total liabilities and equity	505	499	440	385	328	342	264	211	202	187	149	237
Common shares outstanding (cover page) millions of shares	82	82	82	82	83	83	84	90	98	98	98	154

Fiscal quarters (EDIT's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(45)	(19)*	(62)	(68)	(62)	(45)*	(76)	(53)	(25)	(6)*	(25)	(18)
Stock-based compensation	5*	5*	8	5*	5*	4*	3	3*	2*	2*	2	2*
Net cash from operating activities	(35)*	(22)*	(50)	(57)*	(53)*	(51)*	(48)	(50)*	(31)*	(36)*	(23)	(30)*
Purchases of property and equipment	0*	1*	2	3*	3*	1*	0	0*	0*	0*	0	0*
Net cash from investing activities	(103)*	63*	(5)	52*	84*	31*	56	43*	40*	0*	0	(30)*
Proceeds from issuing common stock	0*	0*	0	0*	0*	0*	1	7*	17*	17*	0	117*
Net cash from financing activities	0*	1*	0	0*	0*	56*	(1)	7*	17*	17*	0	118*
Net change in cash	(138)*	41*	(54)	(5)*	31*	36*	7	(0)*	26*	(19)*	(23)	58*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Editas Medicine	182	12	(30)*	153.6M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Palvella Therapeutics	188	not reported	(13)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156	80	(28)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Rezolute	11	not reported	(13)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Cardiff Oncology	9.2	0.1	(12)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72	0	1.5*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Crescent Biopharma	172	0	(19)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Mersana Therapeutics	56	11	(3.2)*	5.0M	17.7 quarters	Q3 FY25 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.